Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients by Ye, Zhong et al.
Postoperative hyperphosphatemia significantly associates with
adverse survival in colorectal cancer patients
Zhong Ye1, Juan P. Palazzo2, Liz Lin1, Yinzhi Lai1, Fran Guiles3, Ronald E. Myers1, Jin
Han4, Jinliang Xing5, and Hushan Yang1,*
1Division of Population Science, Department of Medical Oncology, Kimmel Cancer Center,
Thomas Jefferson University, Philadelphia, PA 19107, USA
2Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
3Oncology Data Service, Thomas Jefferson University, Philadelphia, PA 19107, USA
4Department of Pharmacy, Rush University Medical Center, Chicago, IL 60612
5Experimental Teaching Center, Fourth Military Medical University, Xi’an, 710032, China
Abstract
Background—Hyperphosphatemia has been implicated in the development and treatment of
various cancers. However, whether it can be used as a direct prognostic marker of colorectal
cancer (CRC) has remained unexplored. Given new insights into the importance of
hyperphosphatemia in CRC, we sought to evaluate the association of hyperphosphatemia with the
clinical outcomes of this disease.
Methods—In a retrospective analysis of a well-characterized clinic-based cohort with 1,241
CRC patients, we assessed the association of postoperative hyperphosphatemia with patient
overall survival.
Results—Postoperative hyperphosphatemia measured within the first month after surgery was
significantly associated with CRC survival. Compared to patients with a normal phosphate level,
those with hyperphosphatemia exhibited a significant unfavorable overall survival with a hazard
ratio (HR) of 1.84 (95% confidence interval [CI] 1.49–2.29, P=2.6×10−8, (log-rank P=1.2×10−7).
Stratified analyses indicated the association was more pronounced in patients with colon
(HR=2.00, 95% CI 1.57–2.56, P=3.17×10−8) but not rectal cancer (HR=0.96, 95% CI 0.58–1.59,
P=0.889) (P interaction=0.023), as well as in those not receiving chemotherapy (HR=2.15, 95% CI
1.59–2.90, P=6.2×10−7) but not in those receiving chemotherapy (HR=1.30, 95% CI 0.92–1.82,
P=0.136) (P interaction=0.012). Flexible parametric survival model demonstrated that the
increased risk for death conferred by postoperative hyperphosphatemia persisted over 150 months
after surgery.
Conclusion—Our data indicated that postoperative hyperphosphatemia might be used as a
prognostic marker of CRC patients after surgery. Since phosphate level is routinely tested in
clinics, it may be incorporated into clinical models to predict CRC survival.
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INTRODUCTION
Worldwide, colorectal cancer (CRC) is the third most commonly diagnosed cancer in males
and the second in females 1. According to the American Cancer Society, the year of 2012
will witness approximately 143,460 new cases and 51,690 deaths of CRC in the United
States 2, 3. Despite the recent reduction in CRC mortality, our understanding of its treatment
and prognosis remains limited 4. To further develop prognostic markers has important
clinical value in the management of this devastating disease.
Phosphate, the most abundant mineral in the body, plays a fundamental role in several basic
cellular functions such as energy metabolism, intracellular signaling, and bone and tooth
mineralization 5, 6. However, hyperphosphatemia, defined as having an excessive phosphate
level (≥4.5 mg/dL), has emerged as a risk factor for diseases such as chronic kidney disease
(CKD) and cardiovascular diseases 7–13. Moreover, increasing evidence in case reports and
systemic reviews has focused attention on hyperphosphatemia in the development and
treatment of various solid tumors including CRC 14–21. A cases report showed patient
deterioration and death by acute renal failure in metastatic CRC with hyperphosphatemia 18.
Rapid elevation of phosphate levels may instigate sudden cardiac arrest and acute renal
failure associated with metastatic CRC 19. During cancer development and treatment,
hyperphosphatemia may appear in rare events when tumor cells release metabolic contents
into the bloodstream, either spontaneously or in response to therapy 22, 23. The metabolic
disturbance may progress to clinical toxic effects, including renal insufficiency, cardiac
arrhythmias, and death due to multi-organ failure 23, 24. In a study that used the serum
phosphate level of 110 patients to predict survival time in multiple myeloma, Umeda et al.
found that hyperphosphatemia conferred a shorter survival time and was a negative
prognostic factor 25. Nonetheless, to date, few studies have followed postoperative serum
phosphate levels in CRC patients. To the best of our knowledge, no large clinical cohort
study has been reported to assess hyperphosphatemia as a biomarker to directly predict the
survival in CRC patients. In this study, we sought to evaluate the association between
postoperative phosphate level and overall survival in a clinic-based cohort of 1,241 CRC
patients.
PATIENTS AND METHODS
Study population
The subjects in this study were selected from an existing and ongoing clinic-based cohort
with histologically confirmed CRC patients who visited the Thomas Jefferson University
Hospital (TJUH) since 1990. This study included 1,241 patients who: (1) had a definitive
diagnosis of pathologically confirmed adenocarcinoma of CRC between January 1999 and
January 2012; (2) had a definitive initial diagnostic date; (3) underwent surgery with a
definitive surgery date; and (4) had a phosphate level measurement within the first month
after surgery date (Table 1). Diagnosis dates of the patients ranged from August 1998 to
January 2011. This study was approved by the Institutional Review Board of Thomas
Jefferson University.
Collection of demographic and clinical data
Demographic and clinical data were obtained through medical chart review. Demographic
variables analyzed in this study included age, gender, ethnicity, smoking status, and drinking
status. Clinicopathologic variables included primary tumor site, tumor stage, tumor grade,
and treatment (surgery, chemotherapy, and radiation therapy). Phosphate level was
measured through routine clinical laboratory tests and the values were obtained from chart
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review. The average, maximum, and first time measurements of phosphate level during the
first month after surgery were analyzed in this study.
Statistical analysis
The clinical endpoint analyzed in this study was overall survival which was defined as the
time from initial surgery to death from any cause. Determination of hyperphosphatemia was
based on a clinical cut-off of 4.5 mg/dL as previously defined 26. In addition, analyses based
on the median, tertile, or quartile cut-off was also conducted. The associations between the
average, maximum, or first time measured phosphate level and patient survival were
estimated using hazard ratio (HR) and 95% confidence interval (95% CI) calculated by
multivariate Cox proportional hazards model adjusting for age, gender, ethnicity, smoking
status, drinking status, primary tumor site, tumor stage, tumor grade, chemotherapy, and
radiation therapy, where appropriate. Survival curves were constructed using the Kaplan-
Meier method and compared using the log-rank test. Interaction analysis was performed by
adding an interaction term into the Cox model. Time-dependent effects of phosphate level
on CRC outcomes were analyzed using a flexible parametric survival model with a restricted
cubic spline function. SAS (Version 9.3, SAS Institute, Cary, NC) and STATA (Version
11.0, STATA Corp., College station, TX) software packages were used for these analyses.
All P values were 2-sided, with P ≤ 0.05 considered the threshold of statistical significance.
RESULTS
Characteristics of the study population
The distributions of patient demographics and clinicopathologic variables are listed in Table
1. A total of 1,241 CRC patients with an average age of 65.9 (Standard deviation, 13.3) were
included in the analysis of this study. There were 539 (43.4%) patients identified as being
dead and 702 (56.6%) alive during a median follow-up duration of 39.7 months. Other data
included the distributions of females and males (49.8% vs. 50.2%), ever smokers and never
smokers (47.8% vs. 47.0%), and ever drinkers and never drinkers (47.3% vs. 45.1%). Most
patients were Caucasian (76.9%), with the primary tumor site in the colon (72.6%),
moderately differentiated tumor grade (838, 67.5%), and early stage disease (stages 0, 1, and
2, 57.6%). Less than half of the patients had received chemotherapy (40.3%) and only
16.8% of patients received radiation therapy.
The association of postoperative phosphate level and CRC survival
The associations of postoperative phosphate level by the average, maximum, or first time
measured concentration during the first month following surgical procedure (excluding the
day of surgery) and CRC survival were analyzed using multivariate Cox proportional hazard
model and the results were displayed in Table 2. Compared to patients with a normal
phosphate concentration range (<4.5mg/dL) by the maximum phosphate concentration
during the first month after surgery, those with hyperphosphatemia (defined as phosphate
concentrations ≥4.5mg/dL) exhibited a significant unfavorable overall survival (HR=1.84,
95%CI 1.49–2.29, P=2.6×10−8) (Table 2). Comparison of major demographical and clinical
characteristics between patients with normal and elevated phosphate levels did not reveal
significantly different distributions (Supplementary Table 1). When the analysis was
conducted further adjusting the level of creatinine, an important indicator of renal
dysfunction, the results remained highly significant (HR=1.58, 95% CI 1.25–1.99,
P=9.4×10−5) (Supplementary Table 2). Similar results were obtained when the analyses
were conducted by the average (HR=2.86, 95%CI 1.90–4.31, P=5.0×10−7), or the first time
measured phosphate concentration (HR=1.60, 95%CI 1.18–2.16, P=0.0023) (data not
shown). Consistently, Kaplan-Meier curves indicated patients with hyperphosphatemia
(median survival time, 93.6 months) showed a significantly unfavorable survival (log-rank
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P=1.2×10−7) compared to those with normal phosphate levels (median survival time, 55.5
months (Fig. 1 and Table 2). We further conducted similar analyses using the median,
tertile, and quartile cut-off values of postoperative phosphate level and the results indicated
that the association between high phosphate and poor CRC survival were dose-dependent
(Supplementary Table 3).
Stratified analysis of the effect of postoperative phosphate level on CRC survival
In stratified analysis, the association between hyperphosphatemia and CRC survival
remained significant in both strata of most variables, including age, gender, ethnicity,
smoking status, drinking status, primary tumor site, tumor stage, tumor grade, and radiation
therapy (Table 3). However, the association was only significant in patients with colon
(HR=2.00, 95% CI 1.57–2.56, P=3.17×10−8) but not rectal cancer (HR=0.96, 95% CI 0.58–
1.59, P=0.889) (P interaction=0.023), and in those not receiving chemotherapy (HR=2.15,
95% CI 1.59–2.90, P=6.2×10−7) but not in those receiving chemotherapy (HR=1.30, 95% CI
0.92–1.82, P=0.136) (P interaction=0.012). A significant interaction between
hyperphosphatemia and gender was also observed (P interaction=0.027) (Table 3).
Time-dependent effects of postoperative phosphate level on CRC survival
We analyzed the time-dependent effect of postoperative phosphate level on CRC survival
using a flexible parametric modeling framework adjusting all major host variables (Fig. 2).
We found that the increased risk of death by phosphate level persisted over 150 months and
the risk keeps increasing over time after an initial U shape decrease at 7.5 month after
surgery (Fig. 2).
DISCUSSION
A few previous case reports and small-scale clinical studies have implicated
hyperphosphatemia as a complication in the management of several solid tumors including
CRC 14–21. To the best of our knowledge, the current study is the first that comprehensively
evaluated postoperative phosphate level using a large and well-characterized clinical CRC
patient cohort. We substantiated the prognostic value of phosphate level using an
epidemiological approach and reported interaction effects between phosphate and clinical
variables such as primary tumor site and chemotherapy use. Moreover, we demonstrated that
the association between postoperative hyperphosphatemia and patient survival might persist
for long time after surgery.
The unfavorable prognosis conferred by elevated phosphate level could be explained by
many factors such as the development of metabolic disturbances, use of prophylactic agents,
treatment-related complications like infections or organ failures, or the development of
cardiovascular complications 21, 27, 28. Hyperphosphatemia may develop spontaneously 20 or
associated with tumor lysis syndrome (TLS), a rare event that is sometimes observed in
rapidly proliferating tumors or triggered by systemic cytotoxic treatments 14, 29–32.
However, these complications associated with elevated phosphate level in CRC management
are relatively rare and mostly documented in case reports or small-scale clinical studies.
Therefore, their contributions to the explanation of the effect on CRC survival by elevated
phosphate level observed in the present study remain elusive. Since phosphate and its
derivatives also play an essential role in a wide spectrum of molecular and cellular
functions, especially protein kinase-mediated signaling pathways, whether the unfavorable
prognosis conferred by high phosphate level may be potentially related to disturbed
signaling transductions during treatment remains an interesting topic for future
investigations. In stratified analysis, we observed a significant interaction effect between
phosphate and primary tumor site on CRC survival. The association between high phosphate
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level and poor survival was only evident in colon but not rectal cancer patients. Similar
interaction effect was noticed between phosphate and the use of chemotherapy as the effect
was much more pronounced in patients without chemotherapy compared to those receiving
chemotherapy. The mechanisms of these observations are unknown. Although colon and
rectal cancers generally have similar path of oncogenic development and receive similar
treatment modalities, there are minor differences in their treatment plans on surgery and
cytotoxic therapies, due to the differences in tumor locations and other factors, according to
the treatment guidelines of the National Comprehensive Cancer Network 33. It may be
possible that some complications associated with high phosphate level are more prevalent in
colon cancer patients or mitigated by the use of chemotherapy. Also, we cannot rule out the
possibility of false positive findings due to small sample size in the stratified analysis, since
the significant interactions disappeared after correction for multiple comparisons (data not
shown). Larger and more homogeneous patient populations are needed to further test these
results.
The flexible parametric model network has been used in previous cancer prognosis studies
and clinical trials 34–36. In this study, we applied this model to test the association between
phosphate level and the long-term survival of CRC patients. We observed a persistently
higher chance of death in those patients with hyperphosphatemia over the entire follow-up
period of up to 150 months in this study. Moreover, the risk appeared to keep increasing
over time after an initial drop at 7.5 month after surgery (Fig. 2). Although the confidence
interval of this analysis increasingly widened along with time due to the smaller number of
patients with longer follow-up, its lower limit did not reached 1, indicating the observation
remained statistically significant across the analyzed time period. These results were
consistent with the main effects analysis and strongly corroborated the role of postoperative
phosphate level in predicting CRC survival.
Our study has several strengths. We had a large population of 1,241 CRC patients from a
single institute. The study was focused on the extensive analysis of a single variable and,
thus, did not have the multiple comparison issue. The findings were highly statistically
significant in both the Cox regression and the log-rank analyses. There are also limitations in
our study. Because this study used archived clinical data obtained from chart review instead
of data collected from questionnaire interview in prospective cohorts, missing values in
some variables were noticed. Another limitation is the small number of hyperphosphatemic
patients (N=206) included in the analysis. Although the results derived using these patients
are highly significant, validation studies with larger populations of hyperphospatemic
patients are warranted to further confirm our findings. Because we did not have complete
information on relevant co-morbidities such as renal dysfunction or cardiovascular diseases
that may be associated with CRC prognosis and confound our findings, we were not able to
adjust the effects of these events in the multivariate survival analysis. Therefore, our data,
although highly statistically significant, need to be further substantiated in more rigorous
studies using large independent and prospective populations with a more comprehensive
data collection.
Taken together, we presented one of the first epidemiologic studies elucidating the role of
hyperphosphatemia in CRC prognosis. Our results suggest that postoperative blood
phosphate level is significantly associated with CRC survival. Since phosphate level is
routinely tested in clinics, if validated, it may be incorporated with other factors to develop
clinical models for the prediction of CRC prognosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Kaplan-Meier curve of the analyses between postoperative phosphate level and CRC
survival, evaluated by the maximum values of phosphate level measured with one month
after surgery.
Ye et al. Page 8
J Gastroenterol Hepatol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Time-dependent effect of postoperative phosphate level on CRC survival. The analysis was
adjusted for age, gender, ethnicity, tumor stage, tumor grade, chemotherapy, radiation
therapy and surgery. Solid lines indicated hazard ratios and shaded areas showed the 95%
confidence intervals. Dash lines represented the references.
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Table 1
Characteristics of CRC patients included in this study
Variables Number of patients N=1241, (%)
Age (mean ± SD*) 65.9 ± 13.3
Gender
 Female 618 (49.8)
 Male 623 (50.2)
Ethnicity
 Black 223 (18.0)
 Caucasian 954 (76.8)
 Others 64 (5.2)
Smoking status
 Ever smokers 593 (47.8)
 Never smokers 583 (47.0)
 Unknown 65 (5.2)
Drinking status
 Ever drinking 587 (47.3)
 Never drinking 560 (45.1)
 Unknown 94 (7.6)
Primary tumor sites
 Colon cancer 901 (72.6)
 Rectum cancer 340 (27.4)
Tumor grades
 Well differentiated 119 (9.6)
 Moderately differentiated 838 (67.5)
 Poorly differentiated 169 (13.6)
 Cell type not determined 115 (9.3)
Tumor stages
 Stage 0 40 (3.2)
 Stage 1 306 (24.7)
 Stage 2 369 (29.7)
 Stage 3 298 (24.0)
 Stage 4 171 (13.8)
 Unknown 57 (4.6)
Radiation therapy
 No 1025 (82.6)
 Yes 209 (16.8)
 Unknown 7 (0.6)
Chemotherapy
 No 684 (55.1)
 Yes 500 (40.3)
 Unknown 57 (4.6)
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Variables Number of patients N=1241, (%)
Vital status
 Alive 702 (56.6)
 Dead 539 (43.4)
*SD, standard deviation.
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